Inhibition	0	10	O
of	11	13	O
angiogenesis	14	26	O
by	27	29	O
the	30	33	O
cancer	34	40	B-Pathological_formation
chemopreventive	41	56	O
agent	57	62	O
conjugated	63	73	B-Drug_or_compound
linoleic	74	82	I-Drug_or_compound
acid	83	87	I-Drug_or_compound
.	87	88	O

Dietary	90	97	O
conjugated	98	108	B-Drug_or_compound
linoleic	109	117	I-Drug_or_compound
acid	118	122	I-Drug_or_compound
(	123	124	O
CLA	124	127	B-Drug_or_compound
)	127	128	O
has	129	132	O
been	133	137	O
shown	138	143	O
previously	144	154	O
to	155	157	O
inhibit	158	165	O
rat	166	169	B-Organism
mammary	170	177	B-Organ
carcinogenesis	178	192	O
.	192	193	O

In	194	196	O
addition	197	205	O
to	206	208	O
direct	209	215	O
effects	216	223	O
on	224	226	O
mammary	227	234	B-Cell
epithelial	235	245	I-Cell
cells	246	251	I-Cell
,	251	252	O
including	252	261	O
decreased	262	271	O
proliferation	272	285	O
and	286	289	O
induction	290	299	O
of	300	302	O
apoptosis	303	312	O
,	312	313	O
CLA	314	317	B-Drug_or_compound
may	318	321	O
exert	322	327	O
its	328	331	O
effects	332	339	O
indirectly	340	350	O
by	351	353	O
inhibiting	354	364	O
the	365	368	O
differentiation	369	384	O
of	385	387	O
mammary	388	395	B-Cell
stromal	396	403	I-Cell
cells	404	409	I-Cell
to	410	412	O
an	413	415	O
endothelial	416	427	B-Cell
cell	428	432	I-Cell
type	433	437	O
.	437	438	O

Specifically	439	451	O
,	451	452	O
CLA	453	456	B-Drug_or_compound
was	457	460	O
found	461	466	O
to	467	469	O
decrease	470	478	O
the	479	482	O
ability	483	490	O
of	491	493	O
mammary	494	501	B-Cell
stromal	502	509	I-Cell
cells	510	515	I-Cell
to	516	518	O
form	519	523	O
complex	524	531	O
anastomosing	532	544	O
microcapillary	545	559	B-Multi-tissue_structure
networks	560	568	I-Multi-tissue_structure
in	569	571	O
vitro	572	577	O
on	578	580	O
Engelbreth	581	591	O
-	591	592	O
Holm	592	596	O
-	596	597	O
Swarm	597	602	O
-	602	603	O
derived	603	610	O
reconstituted	611	624	O
basement	625	633	B-Cellular_component
membrane	634	642	I-Cellular_component
.	642	643	O

This	644	648	O
suggested	649	658	O
that	659	663	O
CLA	664	667	B-Drug_or_compound
might	668	673	O
inhibit	674	681	O
angiogenesis	682	694	O
in	695	697	O
vivo	698	702	O
.	702	703	O

To	704	706	O
test	707	711	O
this	712	716	O
possibility	717	728	O
,	728	729	O
CD2	730	733	O
/	733	734	O
F	734	735	O
(	735	736	O
1	736	737	O
)	737	738	O
mice	739	743	B-Organism
were	744	748	O
placed	749	755	O
on	756	758	O
synthetic	759	768	O
diets	769	774	O
containing	775	785	O
0	786	787	O
,	787	788	O
1	789	790	O
,	790	791	O
or	792	794	O
2	795	796	O
%	796	797	O
CLA	798	801	B-Drug_or_compound
for	802	805	O
6	806	807	O
weeks	808	813	O
,	813	814	O
before	815	821	O
angiogenic	822	832	O
challenge	833	842	O
by	843	845	O
s	846	847	O
.	847	848	O
c	848	849	O
.	849	850	O
injection	851	860	O
with	861	865	O
an	866	868	O
angiogenic	869	879	O
gel	880	883	O
substrate	884	893	O
(	894	895	O
Matrigel	895	903	O
pellet	904	910	O
assay	911	916	O
)	916	917	O
.	917	918	O

After	919	924	O
7	925	926	O
days	927	931	O
,	931	932	O
the	933	936	O
pellets	937	944	O
from	945	949	O
animals	950	957	O
fed	958	961	O
the	962	965	O
control	966	973	O
diet	974	978	O
were	979	983	O
infiltrated	984	995	O
by	996	998	O
abundant	999	1007	O
branching	1008	1017	O
networks	1018	1026	B-Multi-tissue_structure
of	1027	1029	I-Multi-tissue_structure
blood	1030	1035	I-Multi-tissue_structure
vessels	1036	1043	I-Multi-tissue_structure
with	1044	1048	O
patent	1049	1055	O
lumen	1056	1061	B-Immaterial_anatomical_entity
-	1061	1062	O
containing	1062	1072	O
RBCs	1073	1077	B-Cell
.	1077	1078	O

In	1079	1081	O
contrast	1082	1090	O
,	1090	1091	O
pellets	1092	1099	O
from	1100	1104	O
the	1105	1108	O
CLA	1109	1112	B-Drug_or_compound
-	1112	1113	O
fed	1113	1116	O
animals	1117	1124	O
contained	1125	1134	O
fewer	1135	1140	O
infiltrating	1141	1153	O
cells	1154	1159	B-Cell
,	1159	1160	O
which	1161	1166	O
formed	1167	1173	O
limited	1174	1181	O
branching	1182	1191	O
cellular	1192	1200	B-Multi-tissue_structure
networks	1201	1209	I-Multi-tissue_structure
,	1209	1210	O
the	1211	1214	O
majority	1215	1223	O
of	1224	1226	O
which	1227	1232	O
had	1233	1236	O
collapsed	1237	1246	O
lumen	1247	1252	B-Immaterial_anatomical_entity
and	1253	1256	O
no	1257	1259	O
RBCs	1260	1264	B-Cell
.	1264	1265	O

Both	1266	1270	O
levels	1271	1277	O
of	1278	1280	O
dietary	1281	1288	O
CLA	1289	1292	B-Drug_or_compound
showed	1293	1299	O
similar	1300	1307	O
effects	1308	1315	O
,	1315	1316	O
with	1317	1321	O
the	1322	1325	O
number	1326	1332	O
of	1333	1335	O
RBC	1336	1339	B-Cell
-	1339	1340	O
containing	1340	1350	O
vessels	1351	1358	B-Multi-tissue_structure
per	1359	1362	O
20x	1363	1366	O
field	1367	1372	O
decreased	1373	1382	O
to	1383	1385	O
a	1386	1387	O
third	1388	1393	O
of	1394	1396	O
that	1397	1401	O
seen	1402	1406	O
in	1407	1409	O
control	1410	1417	O
.	1417	1418	O

Dietary	1419	1426	O
CLA	1427	1430	B-Drug_or_compound
decreased	1431	1440	O
serum	1441	1446	B-Organism_substance
levels	1447	1453	O
of	1454	1456	O
vascular	1457	1465	B-Gene_or_gene_product
endothelial	1466	1477	I-Gene_or_gene_product
growth	1478	1484	I-Gene_or_gene_product
factor	1485	1491	I-Gene_or_gene_product
(	1492	1493	O
VEGF	1493	1497	B-Gene_or_gene_product
)	1497	1498	O
and	1499	1502	O
whole	1503	1508	O
mammary	1509	1516	B-Organ
gland	1517	1522	I-Organ
levels	1523	1529	O
of	1530	1532	O
VEGF	1533	1537	B-Gene_or_gene_product
and	1538	1541	O
its	1542	1545	O
receptor	1546	1554	O
Flk	1555	1558	B-Gene_or_gene_product
-	1558	1559	I-Gene_or_gene_product
1	1559	1560	I-Gene_or_gene_product
.	1560	1561	O

Both	1562	1566	O
cis	1567	1570	B-Drug_or_compound
-	1570	1571	I-Drug_or_compound
9	1571	1572	I-Drug_or_compound
,	1572	1573	O
trans	1574	1579	B-Drug_or_compound
-	1579	1580	I-Drug_or_compound
11	1580	1582	I-Drug_or_compound
and	1583	1586	O
trans	1587	1592	B-Drug_or_compound
-	1592	1593	I-Drug_or_compound
10	1593	1595	I-Drug_or_compound
,	1595	1596	O
cis	1597	1600	B-Drug_or_compound
-	1600	1601	I-Drug_or_compound
12	1601	1603	I-Drug_or_compound
CLA	1604	1607	I-Drug_or_compound
isomers	1608	1615	I-Drug_or_compound
were	1616	1620	O
effective	1621	1630	O
in	1631	1633	O
inhibiting	1634	1644	O
angiogenesis	1645	1657	O
in	1658	1660	O
vitro	1661	1666	O
in	1667	1669	O
a	1670	1671	O
dose	1672	1676	O
-	1676	1677	O
dependent	1677	1686	O
fashion	1687	1694	O
.	1694	1695	O

The	1696	1699	O
ability	1700	1707	O
of	1708	1710	O
CLA	1711	1714	B-Drug_or_compound
to	1715	1717	O
inhibit	1718	1725	O
angiogenesis	1726	1738	O
may	1739	1742	O
contribute	1743	1753	O
to	1754	1756	O
its	1757	1760	O
efficacy	1761	1769	O
as	1770	1772	O
a	1773	1774	O
chemopreventive	1775	1790	O
agent	1791	1796	O
.	1796	1797	O

